BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
pharmaphorum1d
Beyond COVID-19: mRNA vaccines aim to revolutionise cancer care
The mRNA vaccine, known as BNT116, is being developed by BioNTech and is targeting the treatment of non-small cell lung cancer (NSCLC). The phase 2 trial will recruit 130 participants across seven ...